* Collegium Pharmaceutical Inc COLL.OQ COLL.O is
expected
to show a rise in quarterly revenue when it reports results on
February 23.
* The Stoughton Massachusetts-based company is expected to
report
a 357.5% increase in revenue to $125.193 million from $27.36
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. The company's guidance on
February 6 2023, for the period ended December 31, was for
revenue between $125.70 million and $128.20 million.
* Refinitiv's mean analyst estimate for Collegium
Pharmaceutical
Inc is for a loss of 14 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Collegium
Pharmaceutical Inc is $36, above its last closing price
of $25.94.
The company's guidance on February 6 2023 for the period ended
December 31 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between USD125.7 million and
USD74.4 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.19 -0.13 0.01 Beat 107.4
Jun. 30 2022 1.38 1.42 0.32 Missed -77.5
Mar. 31 2022 0.90 0.90 0.44 Missed -50.9
Dec. 31 2021 1.06 1.04 -0.51 Missed -149.2
Sep. 0.95 0.95 0.22 Missed -76.9
30 2021
Jun. 30 2021 0.36 0.47 0.27 Missed -42.8
Mar. 31 2021 0.30 0.42 0.41 Missed -2.8
Dec. 31 2020 0.28 0.39 0.20 Missed -48.5
This summary was machine generated February 22 at 03:02 GMT.
All figures in US dollars unless otherwise stated